Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M

Whitehawk Therapeutics, Inc.

2024-Q3 EPS reported -$1.68 revenue$18,744,000

FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.
Net loss of $12.5M for Q3 2024 vs $16.3M for Q3 2023; operating expenses $20.6M incl $2.6M restructuring.
Cash, equivalents, and short-term investments $62.6M as of Sep 30, 2024; expected to fund ops into 2H 2026.
Completed wind-down of PRECISION1 trial; Phase 2 trials for EEC and NETs enrolled 24 and 12 patients.
Comprehensive strategic review ongoing to maximize shareholder value; no timeline provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.